Development of a Steady-state FRET-based Assay to Identify Inhibitors of the Keap1-Nrf2 Protein-protein Interaction

Overview

Journal Protein Sci

Specialty Biochemistry

Date 2013 Oct 17

PMID 24130096

Citations 12

Authors

Marjolein Schaap

Rowena Hancock

Andrew Wilderspin

Geoff Wells

Affiliations

Soon will be listed here.

Abstract

One of the strategies proposed for the chemoprevention of degenerative diseases and cancer involves upregulation of antioxidant and free radical detoxification gene products by increasing the intracellular concentration of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). This can be achieved by disrupting the interaction between Nrf2 and Kelch-like ECH associated protein 1 (Keap1), a substrate adaptor protein for a Cul3-dependent E3 ubiquitin ligase complex. Here, we describe the development of a high-throughput fluorescence (or Förster) resonance energy transfer assay for the identification of inhibitors of the Keap1-Nrf2 protein-protein interaction (PPI). The basis of this assay is the binding of a YFP-conjugated Keap1 Kelch binding domain to a CFP-conjugated Nrf2-derived 16-mer peptide containing a highly conserved "ETGE" motif. The competition aspect of the assay was validated using unlabeled Nrf2-derived 7-mer and 16-mer peptides and has potential as a screening tool for small molecule inhibitors of the PPI. We discuss the development of this assay in the context of other methods used to evaluate this PPI.

Citing Articles

A novel mRNA decay inhibitor abolishes pathophysiological cellular transition.

Kami D, Ishizaki T, Taya T, Katoh A, Kouji H, Gojo S Cell Death Discov. 2022; 8(1):278.

PMID: 35672286 PMC: 9174231. DOI: 10.1038/s41420-022-01076-4.

Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.

Lee S, Abed D, Beamer L, Hu L SLAS Discov. 2020; 26(1):100-112.

PMID: 32564647 PMC: 10506337. DOI: 10.1177/2472555220935816.

Development of an enzyme-linked immunosorbent assay for Keap1-Nrf2 interaction inhibitors identification.

Wang Y, Xiao C, Lin H, Hu J, Ip T, Wan D Redox Biol. 2020; 34:101573.

PMID: 32422542 PMC: 7231848. DOI: 10.1016/j.redox.2020.101573.

Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.

Lee S, Hu L Med Chem Res. 2020; 29(5):846-867.

PMID: 32390710 PMC: 7207041. DOI: 10.1007/s00044-020-02539-y.

Beyond repression of Nrf2: An update on Keap1.

Kopacz A, Kloska D, Forman H, Jozkowicz A, Grochot-Przeczek A Free Radic Biol Med. 2020; 157:63-74.

PMID: 32234331 PMC: 7732858. DOI: 10.1016/j.freeradbiomed.2020.03.023.

References

Manson M, Gescher A, Hudson E, Plummer S, Squires M, Prigent S . Blocking and suppressing mechanisms of chemoprevention by dietary constituents. Toxicol Lett. 2000; 112-113:499-505. DOI: 10.1016/s0378-4274(99)00211-8. View

Inoyama D, Chen Y, Huang X, Beamer L, Kong A, Hu L . Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. J Biomol Screen. 2011; 17(4):435-47. PMC: 3309107. DOI: 10.1177/1087057111430124. View

Piston D, Kremers G . Fluorescent protein FRET: the good, the bad and the ugly. Trends Biochem Sci. 2007; 32(9):407-14. DOI: 10.1016/j.tibs.2007.08.003. View

Tong K, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M . Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006; 26(8):2887-900. PMC: 1446969. DOI: 10.1128/MCB.26.8.2887-2900.2006. View

Hayes J, McMahon M, Chowdhry S, Dinkova-Kostova A . Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010; 13(11):1713-48. DOI: 10.1089/ars.2010.3221. View

Hancock R, Schaap M, Pfister H, Wells G . Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity. Org Biomol Chem. 2013; 11(21):3553-7. DOI: 10.1039/c3ob40249e. View

Marcotte D, Zeng W, Hus J, McKenzie A, Hession C, Jin P . Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem. 2013; 21(14):4011-9. DOI: 10.1016/j.bmc.2013.04.019. View

Liang Y . Applications of isothermal titration calorimetry in protein science. Acta Biochim Biophys Sin (Shanghai). 2008; 40(7):565-76. DOI: 10.1111/j.1745-7270.2008.00437.x. View

Baird L, Lleres D, Swift S, Dinkova-Kostova A . Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci U S A. 2013; 110(38):15259-64. PMC: 3780858. DOI: 10.1073/pnas.1305687110. View

10.

Neumann T, Junker H, Schmidt K, Sekul R . SPR-based fragment screening: advantages and applications. Curr Top Med Chem. 2007; 7(16):1630-42. DOI: 10.2174/156802607782341073. View

11.

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

12.

Prochaska H, Santamaria A . Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem. 1988; 169(2):328-36. DOI: 10.1016/0003-2697(88)90292-8. View

13.

Hu L, Magesh S, Chen L, Wang L, Lewis T, Chen Y . Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett. 2013; 23(10):3039-43. PMC: 3648997. DOI: 10.1016/j.bmcl.2013.03.013. View

14.

Nkansah E, Shah R, Collie G, Parkinson G, Palmer J, Rahman K . Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography. FEBS Lett. 2013; 587(7):833-9. DOI: 10.1016/j.febslet.2013.01.065. View

15.

Martin S, Tatham M, Hay R, Samuel I . Quantitative analysis of multi-protein interactions using FRET: application to the SUMO pathway. Protein Sci. 2008; 17(4):777-84. PMC: 2271167. DOI: 10.1110/ps.073369608. View

16.

Pollok B, HEIM R . Using GFP in FRET-based applications. Trends Cell Biol. 1999; 9(2):57-60. DOI: 10.1016/s0962-8924(98)01434-2. View

17.

Magesh S, Chen Y, Hu L . Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012; 32(4):687-726. PMC: 3393814. DOI: 10.1002/med.21257. View

18.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

19.

WATTENBERG L . Chemoprevention of cancer. Cancer Res. 1985; 45(1):1-8. View

20.

Dinkova-Kostova A, Holtzclaw W, Cole R, Itoh K, Wakabayashi N, Katoh Y . Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002; 99(18):11908-13. PMC: 129367. DOI: 10.1073/pnas.172398899. View